Advancements in nanocarrier-mediated sunitinib delivery: Addressing obstacles and revealing its therapeutic promise in oncological treatment
Mohammad Javad Javid-Naderi,Zohreh Abbasi,Sonia Fathi-karkan,Mehdi Shahgolzari,Reza Maleki-baladi,Fahimeh Shayegh,Ailin Ebrahimzadeh,Behnaz Banimohamad-Shotorbani,Abbas Rahdar,Meisam Babaei,Sadanand Pandey
DOI: https://doi.org/10.1016/j.jddst.2024.106107
IF: 5
2024-09-03
Journal of Drug Delivery Science and Technology
Abstract:Highlights • Nanocarrier systems for Sunitinib improve therapeutic efficacy and reduce side effects by addressing issues like poor water solubility, low bioavailability, and systemic toxicity. • The combination of nanotechnology and cancer therapeutics enhances treatment accuracy by targeting solid tumors with epidermal growth factor receptors (EGFRs), minimizing cytotoxicity. • Key obstacles include optimizing nanoparticle size, shape, and surface chemistry to improve cellular absorption, biodistribution, and overall effectiveness. • Translating lab innovations to clinical applications faces challenges like scalability, reproducibility, and meeting regulatory requirements for consistent quality and efficacy. • Focus on innovative nanocarrier systems, multi-drug delivery, and theranostics to enhance targeting, control drug release, and integrate diagnostic and therapeutic capabilities for personalized medicine. Sunitinib, a versatile receptor tyrosine kinase inhibitor, shows significant clinical effectiveness against various cancers. However, its therapeutic use is limited by non-specific distribution, low bioavailability, and poor water solubility. This study explores nanocarrier-based methods to overcome these challenges and improve sunitinib delivery. The focus is on inorganic nanostructures, stimuli-responsive polymers, and lipid-based nanoparticles, including graphene and carbon nanotubes, highlighting their potential to enhance drug dosage, enable targeted delivery, and control release. The combination of sunitinib with other treatments to combat multidrug resistance is also examined. The challenges of nanoparticle use, such as improving efficacy, targeted delivery, and regulatory issues, are discussed along with future research directions. The integration of theranostic capabilities with multi-drug delivery systems could personalize cancer treatment. This analysis underscores the potential of nanotechnology to improve sunitinib distribution and efficacy in cancer therapy. Graphical abstract Download: Download high-res image (297KB) Download: Download full-size image
pharmacology & pharmacy